Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal?

References

• Kroll MH, Reséndiz JC. Mechanisms of platelet activation. In: Thrombosis and Hemorrhage. Third Edition. J Loscalzo, AI Schafer (Eds). Lippincott Williams and Wilkins, NY, USA (2003).
   Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nature Med. 8, 1227–1234 (2002).
   PubMed Web of Science ®Google Scholar
• Gibbons JM. Platelet adhesion signaling and the regulation of thrombus formation. J. Cell Sci. 117, 3415–3425 (2004).
   PubMedGoogle Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Kato, K, Kanaji T, Russell S et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102, 1701–1707 (2003).
   PubMed Web of Science ®Google Scholar
• Sadler JE. Contact – how platelets touch von Willebrand factor. Science 297, 1128–1129 (2002).
   PubMedGoogle Scholar
• Grϋner S, Prostredna M, Shulte V et al. Multiple integrin–ligand interactions synergize in shear-resistant adhesion at sites of arterial injury. Blood 102, 4021–4027 (2003).
   PubMedGoogle Scholar
• Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606–1615 (2004).
   PubMed Web of Science ®Google Scholar
• Kroll MH, Feng S. Determinants of glycoprotein Ib-mediated hemostasis versus thrombosis. In Microvascular Research: Biology and Pathology. Shepro D (Ed.). Elsevier, MA, USA (2005).
   Google Scholar
• Kao S-H, McIntire LV. Rheology. In: Thrombosis and Hemorrhage. Third Edition. Loscalzo J, Schafer AI (Eds). Lippincott Williams and Wilkins, NY, USA (2003).
   Google Scholar
• Reed G. Platelet secretory mechanisms. Semin. Thromb. Hemost. 30, 441–450 (2004).
   PubMed Web of Science ®Google Scholar
• Hartwig JH. Platelet morphology and shape change. In: Thrombosis and Hemorrhage. Third Edition. Loscalzo J, Schafer AI (Eds). Lippincott Williams and Wilkins, NY, USA (2003).
   Google Scholar
• Tadokoro S, Shattil SJ, Eto K et al. Talin binding to integrin β tails: a final common step in integrin activation. Science 302, 103–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Li R, Mitra N, Gratkowski H et al. Activation of integrin αIIbβ3 by modulation of transmembrane helix associations. Science 300, 795–798 (2004).
   Google Scholar
• Vinogradova O, Velyvis A, Velyviene A et al. A structural mechanism of integrin αIIbβ3 ‘inside-out’ activation as regulated by its cytoplasmic face. Cell110, 587–597 (2002).
   PubMed Web of Science ®Google Scholar
• Li W, Metcalf DG, Gorelik R et al. A push–pull mechanism for regulating integrin function. Proc. Natl Acad. Sci. 102, 1424–1429 (2005).
   PubMed Web of Science ®Google Scholar
• Yan B, Calderwood DA, Yaspan B, Ginsberg MH. Calpain cleavage promotes talin binding to the β3 integrin cytoplasmic domain. J. Biol. Chem. 276, 28164–28170 (2001).
   PubMedGoogle Scholar
• Martel V, Racaud-Sultan C, Dupe S et al. Conformation, localization, and integrin binding of talin depend on its interaction with phosphoinositides. J. Biol. Chem. 276, 21217–21227 (2001).
   PubMed Web of Science ®Google Scholar
• Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. J. Biol. Chem. 267, 11300–11306 (1992).
   PubMed Web of Science ®Google Scholar
• Olson JD, Zaleski A, Herrmann D, Flood PA. Adhesion of platelets to purified solid-phase von Willebrand factor: effects of wall shear rate, ADP, thrombin and ristocetin. J. Lab. Clin. Med. 14, 6–18 (1989).
   Google Scholar
• Navdaev A, Clemetson KJ. Glycoprotein Ib cross-linking/ligation on echicetin-coated surfaces or echicetin-IgMk in stirred suspension activates platelets by cytoskeleton modulated calcium release. J. Biol. Chem. 277, 45928–45934 (2002).
   PubMedGoogle Scholar
• Feng S, Christodoulides N, Reséndiz JC, Berndt MC, Kroll MH. Regulation of 14–3-3ζ protein binding to GpIb/IX/V by the cytoplasmic domains of GpIbα and GpIbβ. Blood 95, 550–557 (2000).
   Google Scholar
• Feng S, Reséndiz JC, Li X, Kroll MH. Filamin A binding to the cytoplasmic domain of glycoprotein Ibα regulates von Willebrand factor-induced platelet activation. Blood 102, 2122–2129 (2003).
   PubMed Web of Science ®Google Scholar
• Feng S, Reséndiz JC, Christodoulides N et al. Pathological shear stress stimulates the tyrosine phosphorylation of α-actinin associated with the glycoprotein GpIb-IX complex. Biochemistry 41, 1100–1108 (2002).
   PubMedGoogle Scholar
• Reséndiz JC, Feng S, Ji G, Kroll MH. von Willebrand factor binding to platelet glycoprotein Ib-IX-V stimulates the assembly of an α-actinin based signaling complex. J. Thromb. Haemostasis 2, 161–169 (2004).
   PubMedGoogle Scholar
• Nesbitt WS, Kulkarni S, Giuliano S et al. Distinct glycoprotein Ib/V/IX and αIIbβ3-dependent calcium signals co-operatively regulate platelet adhesion under flow. J. Biol. Chem. 277, 2965–2972 (2002).
   PubMed Web of Science ®Google Scholar
• Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic signals in a 2-stage platelet activation process induced by the glycoprotein Ibα mechanoreceptor. Blood 100, 2793–2800 (2002).
   PubMed Web of Science ®Google Scholar
• Yap CL, Anderson KE, Hughan SC, Dopheide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3. Blood 99, 151–158 (2002).
   PubMedGoogle Scholar
• Reséndiz JC, Feng S, Ji G, Francis KA, Berndt MC, Kroll MH. Purinergic P2Y receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation. Mol. Pharmacol. 63, 639–645 (2002).
   Google Scholar
• Sun L, Feng S, Reséndiz JC, Lu X, Durante W, Kroll MH. Role of Pky2-MAPK-cPLA2 signaling pathway in shear-induced platelet activation. Ann. Biomed. Engineer. 32, 1193–1201 (2004).
   PubMedGoogle Scholar
• Wu Y, Suzuki-Inoue K, Satoh K et al. Role of Fc receptor γ-chain in platelet glycoprotein Ib-mediated signaling. Blood 97, 3836–3845 (2001).
   PubMed Web of Science ®Google Scholar
• Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-V activates aIIbb3 independently of other receptors. Blood 103, 3403–3411 (2004).
   PubMed Web of Science ®Google Scholar
• Kasirer-Friede A, Ware J, Leng L, Marchese P, Ruggeri ZM, Shattil SJ. Lateral clustering of platelet GpIb-IX complexes leads to upregulation of the adhesive function of αIIbβ3. J. Biol. Chem. 277, 11949–11956 (2002).
   PubMedGoogle Scholar
• Englund GD, Bodnar RJ, Li Z, Ruggeri ZM, Du X. Regulation of von Willebrand factor binding to the platelet glycoprotein Ib-IX by a membrane skeleton-dependent inside-out signal. J. Biol. Chem. 276, 16952–16959 (2001).
   PubMedGoogle Scholar
• Williamson D, Pikovski I, Cranmer SL et al. Interaction between platelet glycoprotein Ibα and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. J. Biol. Chem. 277, 2151–2159 (2002).
   PubMedGoogle Scholar
• Mazzucato M, Cozzi MR, Pradella P, Ruggeri ZM, De Marco L. Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow. Blood 10, 3221–3227 (2004).
   Google Scholar
• Goncalves I, Nesbitt WS, Yuan Y, Jackson SP. Importance of temporal flow gradients and integrin αIIbβ3 mechanotransduction for shear-activation of platelets. J. Biol. Chem. 280, 15430–15437 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nature Med. 6, 507–514 (2005).
   Google Scholar
• Doggett TA, Girdhar G, Lawshé A et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: The GPIbα-vWF tether bond. Biophys. J. 83,194–205 (2002).
   PubMed Web of Science ®Google Scholar
• Geiger B, Bershadsky A. Exploring the neighborhood: adhesion-coupled cell mechanosensors. Cell 110, 139–142 (2002).
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among does, effectiveness, and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, 234S–264S (2004).
   PubMedGoogle Scholar
• Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation106, 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C et al. European stroke prevention study II; dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1–13 (1996).
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemostasis 1, 1710–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Sanderson S, Emery J, Baglin T, Kinmouth A-L. Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 142, 370–380 (2005).
   PubMedGoogle Scholar
• Catella-Lawson F, Reilly MP, Kapoor Sc et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345, 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Jackson SP, Schoenwaelder SM. Antiplatelet therapy – in search of the magic bullet. Nature Rev. Drug Discov. 2, 775–789 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall SJ, Senis YA, Auger JM et al. GPIb-dependent platelet activation is dependent on Src kinases but not MAPKs or cGMP-dependent kinase. Blood 103, 2601–2609 (2004).
   PubMedGoogle Scholar
• Bonnefoy A, Vermylen j, Hoylaerts MF. Inhibition of von Willebrand factor-GpIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev. Cardiovasc. Ther.1, 257–269 (2003).
   PubMedGoogle Scholar